Bedside Snapshot
  • Core dose: Nebulizer 2.5–5 mg every 20 min × 3 for severe bronchospasm (can give continuous 10–15 mg/h); MDI 4–8 puffs every 20 min × 3; hyperkalemia 10–20 mg nebulized
  • Onset/duration: Onset 5–15 min; peak effect 60–90 min; duration 3–6 hours
  • Key danger: Tachycardia, tremor, and hypokalemia (especially with high/repeated doses); use caution in cardiac disease or arrhythmias
  • Special: Selective β2-agonist bronchodilator; can combine with ipratropium for severe exacerbations; causes intracellular K⁺ shift (useful adjunct in hyperkalemia); less effective if patient not breathing deeply
Brand & Generic Names
  • Generic Name: albuterol (U.S.); international name: salbutamol
  • Brand Names: Proventil HFA, Ventolin HFA, ProAir HFA/RespiClick/Digihaler, AccuNeb
Medication Class

Short-acting β2-adrenergic agonist (SABA); bronchodilator

Pharmacology

Mechanism of Action:

  • Selective β2-receptor agonism in airway smooth muscle increases cAMP (via adenylyl cyclase → PKA), producing bronchodilation.
  • Reduces mediator release from mast cells; may enhance mucociliary clearance.
  • Selectivity is dose-dependent; high systemic exposure can stimulate β1 receptors (tachycardia/palpitations).

Pharmacokinetics:

  • Onset: Inhaled onset 5–15 min; peak 60–90 min; duration about 3–6 h.
  • Half-life: ~3–8 h (inhaled/PO range)
  • Protein binding: ~10%
  • Metabolism: Hepatic metabolism (predominantly sulfation to inactive metabolite)
  • Elimination: Renal elimination of parent and metabolites
  • Metabolic effects: Causes intracellular K⁺ shift (transient decrease in serum potassium)
Indications
  • Acute bronchospasm in asthma or COPD exacerbations
  • Prevention of exercise-induced bronchospasm
  • Adjunct in hyperkalemia to temporarily lower serum potassium while definitive therapies are given
Conditions Treated
  • Asthma (acute exacerbation)
  • Chronic obstructive pulmonary disease (COPD) exacerbation
  • Exercise-induced bronchospasm
  • Hyperkalemia (adjunct therapy, off-label)
Dosing & Administration

Available Forms:

  • Metered-dose inhaler (MDI): 90 mcg per actuation
  • Dry powder inhaler (DPI) - RespiClick/Digihaler: 90 mcg per inhalation
  • Nebulizer solution: 0.083% (2.5 mg/3 mL), 0.5% (2.5 mg/0.5 mL), unit-dose 0.63 or 1.25 mg/3 mL

Adult Dosing:

Route / Indication Dose Notes
MDI (Quick-relief) 2 puffs every 4–6 h as needed Maximum 12 puffs/day
MDI (Severe flare) 4–8 puffs via spacer every 20 min for up to 3 doses Use with spacer for better delivery
DPI (RespiClick/Digihaler) 2 inhalations every 4–6 h as needed Maximum 12 inhalations/day
Nebulizer (Moderate–severe exacerbation) 2.5–5 mg every 20 min for 3 doses, then 2.5–10 mg every 1–4 h as needed May use continuous 10–15 mg/h for severe cases
Exercise-induced bronchospasm 2 puffs 15–30 min before activity Preventive dosing
Hyperkalemia (off-label) 10–20 mg via nebulizer over ~10 min Onset ~15 min; effect is temporary

Pediatric Dosing (Nebulized):

  • 0.15 mg/kg (minimum 2.5 mg) every 20 min × 3 doses, then as needed
Contraindications

Contraindications:

  • Hypersensitivity to albuterol or product components
  • Certain DPIs should be avoided in patients with severe milk protein allergy

Precautions:

  • Use with caution in ischemic heart disease, arrhythmias, hypertension, hyperthyroidism, diabetes, or seizure disorders
  • Frequent need or escalating doses indicate poor control—optimize controller therapy and reassess diagnosis/technique
  • May lower serum potassium and increase heart rate; monitor ECG/electrolytes in severe attacks or with high/continuous dosing
Drug Interactions: Nonselective β-blockers may blunt effect; MAOIs/TCAs can potentiate cardiovascular effects; additive hypokalemia with loop/thiazide diuretics; digoxin levels/effects may be altered—monitor as clinically indicated.
Adverse Effects

Common:

  • Tremor
  • Nervousness
  • Tachycardia/palpitations
  • Headache
  • Throat irritation or cough

Metabolic:

  • Hypokalemia
  • Hyperglycemia

Serious (but uncommon):

  • Paradoxical bronchospasm
  • Hypersensitivity reactions
  • QT prolongation/arrhythmias
  • Lactic acidosis with high or prolonged dosing
Clinical Pearls
MDI vs Nebulizer: MDI with spacer provides bronchodilation comparable to nebulization for many patients; select device based on patient status and logistics.
Moderate–Severe Exacerbations: Use repeated or continuous dosing early, then taper as work of breathing and wheeze improve.
Add Ipratropium: In moderate–severe asthma/COPD exacerbations, add ipratropium to improve airflow and reduce admissions.
Hypoxemic Patients: Run nebulizers on oxygen (about 6–8 L/min) when hypoxemic; closely monitor HR, rhythm, potassium, and—if high doses—lactate.
Levalbuterol Alternative: Consider levalbuterol if tremor or tachycardia is limiting, recognizing clinical differences are often modest.
Hyperkalemia Use: Hyperkalemia response is variable (less reliable in ESRD); combine with insulin/glucose and other temporizing measures.
β-Blocker Interaction: Nonselective β-blockers (e.g., propranolol) may attenuate bronchodilation; consider cardioselective agents if a β-blocker is required.
References
  • 1. Papadopoulos, J. (2008). Pocket guide to critical care pharmacotherapy. Humana Press.
  • 2. Medscape. (n.d.). Albuterol (Proventil HFA, Ventolin HFA) – drug monograph. Retrieved 2025-11-12, from https://reference.medscape.com/drug/proventil-hfa-ventolin-hfa-albuterol-343426
  • 3. DrugBank Online. (n.d.). Albuterol (DB01001). Retrieved 2025-11-12, from https://go.drugbank.com/drugs/DB01001
  • 4. Boucher, B. A., Wood, G. C., & Swanson, J. M. (2006). Pharmacokinetic changes in critical illness. Critical Care Clinics, 22(2), 255–271.
  • 5. Medscape. (n.d.). Hyperkalemia: Treatment & management. Retrieved 2025-11-12, from https://emedicine.medscape.com/article/240903-treatment
Back to Medication Index
Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing and formatting this information. All content is reviewed for accuracy.